Pfizer gains global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics in preclinical development for undisclosed autoimmune diseases. It’s the latest in a series of big pharma business deals involving in vivo cell therapy assets and platform technologies.
The post Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal appeared first on MedCity News.